Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Status:
Completed
Trial end date:
2015-10-28
Target enrollment:
Participant gender:
Summary
Advanced ovarian cancer is a high medical need indication. Cure is not available to these
patients and treatment has palliative intent. A proportion of advanced stage ovarian cancer
expresses substantial levels of Claudin 6 (CLDN6), a carcino-embryonic transmembrane protein,
which is absent from normal adult human tissue. IMAB027 is a monoclonal antibody that binds
to CLDN6. Preclinically IMAB027 was shown to inhibit tumor growth and to kill cancer cells by
antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This trial is
a first-in-human dose escalation and dose finding Phase 1 trial of IMAB027 in patients with
recurrent advanced ovarian cancer to assess the safety and tolerability, the
pharmacokinetics, the antitumoral activity and the immunogenicity of IMAB027.
Phase:
Phase 1
Details
Lead Sponsor:
Ganymed Pharmaceuticals AG Ganymed Pharmaceuticals GmbH